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Efficacy of perioperative chemotherapy with advanced non-small-
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Background: In advanced non-small-cell lung cancer (NSCLC), the 
use of combined modality regimens, utilizing chemotherapy, surgery 
and radiotherapy produces modest improvements in median survival, 
but overall survival remains poor. We performed a retrospective study 
of combined modality regimens including prophylactic cranial ir-
radiation (PCI) to evaluated the efﬁcacy on the patients with locally 
advanced NSCLC.
Methods: 30 patients diagnosed as stage lllA - lllB NSCLC from Sep-
tember 2001 to January 2005, received combined modality regimens. 
All patients treated with 100 mg/m2 of cisplatin given for 3 cycles in 
combination with gemcitabine, docetaxel or paclitaxel neoadjuvant 
chemotherapy, followed by surgery, and then received cisplatin-based 
chemotherapy for 3 cycles of adjuvant chemotherapy. Chest radiothera-
py was left to the decision of investigator.
Results: 23 patients (76.7%) had stage lllA disease and 7 patients 
(23.3%) had stage lllB disease. 20 patients received postoperative chest 
radiotherapy and 12 patients received PCI. The median duration of 
follow-up was 23 (7-64) months. The median survival was 27 (9-64) 
months and disease-free survival was 20 (7-64) months. The objec-
tive response rate (2CR+25PR) were 90%. The 1-year overall survival 
rate was 80% and 2-year overall survival rate was 46.7%. Grade 3/4 he-
matologic toxicities adverse drug reactions (ADRs) of neoadjuvant che-
motherapy were neutropenia (n=2) and that of adjuvant chemotherapy 
were neutropenia (n=3) and thrombocytopenia (n=2). Non-hematologic 
grade 3/4 ADRs in adjuvant chemotherapy were nausea. 
Conclusions: This study demonstrated that perioperative chemotherapy 
was feasible and resulted in good response and overall survival. 
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Background: Recent several reports demonstrated that CDDP-based 
adjuvant chemotherapy should be offered as standard care to patients 
after completely resected early stage (pathological stage IB to II) non-
small-cell lung cancer (NSCLC). The cytotoxic effect of the antican-
cer drug CDDP is principally attributable to the formation of bulky 
intrastrand platinum-DNA adducts. Removal of these adducts from 
genomic DNA is mediated by the nucleotide excision repair pathway, a 
critical element of which for this function is the ERCC1 gene. For ad-
vanced NSCLC (inoperable III-IV stage) with chemotherapy combined 
of cisplatin and gemcitabine, Lord, et al. demonstrated that median 
overall survival was signiﬁcantly longer in patients with low ERCC1 
expression tumors compared to patients with high expression tumors 
(61.6 vs. 20.4 weeks). In this study, we investigated whether ERCC1 
mRNA expression level is a predictive factor for survival in patients 
with completely resected NSCLC followed by CDDP-based adjuvant 
chemotherapy.
Material and Methods: Between February 1991 and December 2001, 
86 patients were operated on for NSCLC and received CDDP-based 
chemotherapy postoperatively at the Tokushima University Hospital. 
The clinical ﬁndings of the patient were shown in the following; male: 
female=47:11, mean age=63.2, adenocarcinoma: 33 squamous cell 
carcinoma: 21, stage I: 8, II: 9, III: 37, IV: 4, lobectomy: 47, regimen 
CDDP+VDS: 42, cycle 1:=34, 2:=21.
Only tumor cells were gotten from parafﬁn-embedded tumor specimens 
using laser-captured microdissection (PALM Microlaser Technologies). 
After RNA isolation, cDNA was prepared from each sample. Relative 
cDNA quantitation for ERCC1 and an internal reference gene (a-actin) 
was done using a ﬂuorescence based, real-time detection method (ABI 
PRISM 7700 Sequence Detection System; TaqMan; Applied Biosys-
tems). The rise of the a-actin signal after cycle 31 using the described 
conditions indicated an insufﬁcient amount of mRNA present for the 
subsequent ERCC1 quantitation.
Results: In 58 of parafﬁn-embedded specimen of 86 patients, ercc1 
mRNA expression could be measured. The mean ERCC1 expression, 
relative to the expression of the internal control housekeeping genea-
actin, was 1.29 (range, 0.17 to 3.76). There were no signiﬁcant associa-
tions between ERCC1 levels and any of the factors age (p=0.48), sex 
(p=0.437), histology histology (squamous cell carcinoma (mean: 1.49) 
vs. adenocarcinoma: (1.17), p=0.221), and tumor stage (I (1.64) and II 
(1.54) vs. III (1.19) and IV (0.96); p=0.153). However, there was a ten-
dency that ERCC1 levels was higher in squamous cell carcinoma and 
early stage tumor. A cut-off value 1.1 of ERCC1 level could segregate 
into poor and good prognosis subgroups. The 5 year survival rate of 
patients with high and low ERCC1 was 66.2% and 42.7%, respectively 
(p=0.0531). The patients with high ERCC1 level showed a favor prog-
nosis compared with those with low ERCC1 level.
Conclusion: Although the patients with low ERCC1 level showed a 
favor prognosis for advanced NSCLC (inoperable III-IV stage) with 
CDDP-based chemotherapy, The patients with high ERCC1 level 
showed a favor prognosis in completely resected NSCLC patients with 
an adjuvant CDDP-based chemotherapy.
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Anaemia as prognostic and predictive factor of non-small cell 
lung cancer patients treated with chemo and radiotheraphy 
– retrospective analysis
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Background: Anaemia is one of the most common symptoms of lung 
cancer. The incidence of anaemia depends on clinical stage, kind of 
